December 2004
Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p1
Trade Publication
Reports on the acquisition of the patent license to the clinical-stage compound pumosetrag from Mitsubishi Pharma Corporation by Dynogen Pharmaceuticals Inc. Clinical information on pumosetrag; Coverage of the license acquired by Dynogen; Comments given by Lee R. Brettman, president and CEO of Dynogen, regarding the acquisition of pumosetrag.


Related Articles

  • Apex Bioventures Acquiring Dynogen in $135M Stock Deal. Hollingsworth, Catherine // BioWorld Today;2/7/2008, Vol. 19 Issue 26, p1 

    The article reports on a definitive merger agreement between Apex Bioventures Acquisition Corp. and privately held Dynogen Pharmaceuticals Inc., in a stock deal valued at more than $140 million. Under the deal, Waltham, Massachusetts-based Dynogen would receive an up-front payment of $98 million...

  • Restructuring Watch.  // BioWorld Today;2/26/2009, Vol. 20 Issue 37, p4 

    The article announces that Dynogen Pharmaceuticals Inc. has filed for bankruptcy, with an intention to liquidate under Chapter 7 of the U.S. bankruptcy code. The firm made two attempts in 2008 to increase its finances, first filing for an initial public offering (IPO), and then looking for a...

  • CLINIC ROUNDUP.  // BioWorld Today;11/9/2007, Vol. 18 Issue 219, p2 

    This section offers news briefs concerning clinical trials. CV Therapeutics Inc. reported that a preclinical study of tecadenoson, a selective adenosine A1 agonist, showed effective rate control in an animal model of atrial fibrillation when used with low dose metoprolol. The Phase IIb trial of...

  • Apex Bioventures to Acquire Dynogen: $135M.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p4 

    The article reports on the plan to merge Apex Bioventures Acquisition Corp. of Hillsborough, California to Dynogen Pharmaceuticals Inc. in Waltham, Massachusetts in a stock deal valued at $135 million. Under the agreement, Dynogen receives an up-front payment and two milestone payments, while...

  • Apex Bioventures and Dynogen sign definitive merger agreement.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p18 

    The article focuses on the definitive merger agreement between Apex Bioventures Acquisition Corp. and Dynogen Pharmaceuticals Inc. The agreement provides that Dynogen will become a public company and that its shareholders will receive about $98 million in Apex's stock. It is expected that the...

  • A MESSAGE FROM OUR CEO. Medera, Garvin // Caribbean Beat;Jan/Feb2020, Issue 161, p20 

    No abstract available.

  • CEO James Miller Takes Creative Reins at The Collected Group: Miller now oversees the design and business of Joie, Equipment and Current/Elliott. CLARK, EVAN // WWD: Women's Wear Daily;2/6/2020, p8 

    Heading design, Miller can keep the brands from stepping on each others' toes in the market and also use his number-savvy to help aid in their development. Wearing his ceo hat, Miller said business is good for Collected.

  • CLINIC ROUNDUP.  // BioWorld Today;5/21/2008, Vol. 19 Issue 99, p5 

    This section offers news briefs concerning clinical trials. Treatment for the first patient in the Phase I study of Pegylated recombinant phenylalanine ammonia lyase (PEG-PAL) in phenylketonuria conducted by BioMarin Pharmaceutical Inc. has been initiated. Results from a Phase IIa trial of...

  • Selecting Leaders. Fernandez, Jorge E. // Executive Excellence;Feb2003, Vol. 20 Issue 2, p14 

    Focuses on the recruitment, selection and development practices of chief executive officers (CEO) in the U.S. Assessment of the behavioral style of CEO; Factors considered in promotion of executive; Behavioral characteristics of CEO.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics